Phase I
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
Glympse Bio’s novel injectable mixture of synthetic sensors, which quantify protease activity and predict treatment response in non-alcoholic steatohepatitis (NASH), was demonstrated as safe and well-tolerated in healthy volunteers in a gene expression study of advanced fibrosis.
Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.
It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here’s a look.
Moderna released interim data from the expansion cohort of its ongoing Phase I trial of its mRNA personalized cancer vaccine, mRNA-4157.
PRESS RELEASES